130 related articles for article (PubMed ID: 20719511)
1. Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
Letourneau JJ; Jokiel P; Olson J; Riviello CM; Ho KK; McAleer L; Yang J; Swanson RN; Baker J; Cowley P; Edwards D; Ward N; Ohlmeyer MH; Webb ML
Bioorg Med Chem Lett; 2010 Sep; 20(18):5449-53. PubMed ID: 20719511
[TBL] [Abstract][Full Text] [Related]
2. The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists.
Cowley PM; Baker J; Barn DR; Buchanan KI; Carlyle I; Clark JK; Clarkson TR; Deehan M; Edwards D; Goodwin RR; Jaap D; Kiyoi Y; Mort C; Palin R; Prosser A; Walker G; Ward N; Wishart G; Young T
Bioorg Med Chem Lett; 2011 Jan; 21(1):497-501. PubMed ID: 21075628
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
Pettersson H; Bülow A; Ek F; Jensen J; Ottesen LK; Fejzic A; Ma JN; Del Tredici AL; Currier EA; Gardell LR; Tabatabaei A; Craig D; McFarland K; Ott TR; Piu F; Burstein ES; Olsson R
J Med Chem; 2009 Apr; 52(7):1975-82. PubMed ID: 19338356
[TBL] [Abstract][Full Text] [Related]
4. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.
Kiyoi T; York M; Francis S; Edwards D; Walker G; Houghton AK; Cottney JE; Baker J; Adam JM
Bioorg Med Chem Lett; 2010 Aug; 20(16):4918-21. PubMed ID: 20634067
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor.
Morrison AJ; Adam JM; Baker JA; Campbell RA; Clark JK; Cottney JE; Deehan M; Easson AM; Fields R; Francis S; Jeremiah F; Keddie N; Kiyoi T; McArthur DR; Meyer K; Ratcliffe PD; Schulz J; Wishart G; Yoshiizumi K
Bioorg Med Chem Lett; 2011 Jan; 21(1):506-9. PubMed ID: 21075630
[TBL] [Abstract][Full Text] [Related]
7. Novel benzimidazole-based MCH R1 antagonists.
Carpenter AJ; Al-Barazanji KA; Barvian KK; Bishop MJ; Britt CS; Cooper JP; Goetz AS; Grizzle MK; Hertzog DL; Ignar DM; Morgan RO; Peckham GE; Speake JD; Swain WR
Bioorg Med Chem Lett; 2006 Oct; 16(19):4994-5000. PubMed ID: 16904318
[TBL] [Abstract][Full Text] [Related]
8. Novel thioamide derivatives as neutral CB1 receptor antagonists.
Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
Cowley PM; Baker J; Buchanan KI; Carlyle I; Clark JK; Clarkson TR; Deehan M; Edwards D; Kiyoi Y; Martin I; Osbourn D; Walker G; Ward N; Wishart G
Bioorg Med Chem Lett; 2011 Apr; 21(7):2034-9. PubMed ID: 21334892
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
11. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Alig L; Alsenz J; Andjelkovic M; Bendels S; Bénardeau A; Bleicher K; Bourson A; David-Pierson P; Guba W; Hildbrand S; Kube D; Lübbers T; Mayweg AV; Narquizian R; Neidhart W; Nettekoven M; Plancher JM; Rocha C; Rogers-Evans M; Röver S; Schneider G; Taylor S; Waldmeier P
J Med Chem; 2008 Apr; 51(7):2115-27. PubMed ID: 18335976
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
Richter HG; Benson GM; Bleicher KH; Blum D; Chaput E; Clemann N; Feng S; Gardes C; Grether U; Hartman P; Kuhn B; Martin RE; Plancher JM; Rudolph MG; Schuler F; Taylor S
Bioorg Med Chem Lett; 2011 Feb; 21(4):1134-40. PubMed ID: 21269824
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
Pizzi DA; Leslie CP; Mazzali A; Seri C; Biagetti M; Bentley J; Genski T; Di Fabio R; Contini S; Sabbatini FM; Zonzini L; Caberlotto L
Bioorg Med Chem Lett; 2010 Dec; 20(23):7120-3. PubMed ID: 20951033
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.
Tamura Y; Omori N; Kouyama N; Nishiura Y; Hayashi K; Watanabe K; Tanaka Y; Chiba T; Yukioka H; Sato H; Okuno T
Bioorg Med Chem Lett; 2012 Sep; 22(17):5498-502. PubMed ID: 22853998
[TBL] [Abstract][Full Text] [Related]
15. Diaryl piperidines as CB1 receptor antagonists.
Scott JD; Li SW; Wang H; Xia Y; Jayne CL; Miller MW; Duffy RA; Boykow GC; Kowalski TJ; Spar BD; Stamford AW; Chackalamannil S; Lachowicz JE; Greenlee WJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1278-83. PubMed ID: 20018510
[TBL] [Abstract][Full Text] [Related]
16. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
[TBL] [Abstract][Full Text] [Related]
17. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
[TBL] [Abstract][Full Text] [Related]
18. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
19. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
[TBL] [Abstract][Full Text] [Related]
20. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
